Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

FDA approves IND for KRAS G12C inhibitor JAB-21822

May 4, 2021

Repare initiates phase I trial of oral PKMYT1 inhibitor RP-6306

May 3, 2021

Monte Rosa Therapeutics discloses new protein cereblon modulators

May 3, 2021

Patient dosing begins in phase Ib/II study of CFI-400945 in leukemia

May 3, 2021

A different path to specificity for Ras inhibitors

May 3, 2021

Phase IIb/III study of masitinib in metastatic CRPC meets primary endpoint

April 30, 2021

PRT-1419 shows potent antitumor activity in preclinical models

April 30, 2021

First-in-class KAT6A/KAT6B inhibitor PF-9363 shows antitumor activity against ER+ breast cancer

April 30, 2021

Goldfinch Biopharma discovers CDK5 inhibitors

April 30, 2021

Recurium IP Holdings patents ERK-1 and/or ERK-2 inhibitors

April 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026